SCHEMBL2929403

SCHEMBL2929403

COc1ccc(C(=O)N(C[C@H]2CN(C(=O)OC(C)(C)C)C[C@@H]2Cc2ccccc2)C(C)C)cc1OCCO

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
REN P00797 20/20 0.60
ADRA1A P35348 3/20 0.60
KCNH2 Q12809 3/20 0.60
HTR1A P08908 2/20 0.60
ADRA1D P25100 2/20 0.60
HTR2A P28223 2/20 0.60
ADRA1B P35368 2/20 0.60
HTR2B P41595 2/20 0.60
CYP3A4 P08684 3/20 0.51
ADRA2A P08913 1/20 0.49
ADRA2B P18089 1/20 0.49
OPRM1 P35372 1/20 0.49
PDE3B Q13370 1/20 0.49
PDE3A Q14432 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929401 1.00 REN (0.60) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL2934522 0.94 REN (0.64) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL2934523 0.94 REN (0.64) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL2936436 0.92 REN (0.57) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL2936434 0.92 REN (0.57) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL8258726 0.86 REN (0.52) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL13105262 0.86 REN (0.62) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL3373012 0.86 REN (0.62) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL3373009 0.86 REN (0.62) RENADRA1AKCNH2HTR1AADRA1D
SCHEMBL2939821 0.85 REN (0.59) RENADRA1AKCNH2HTR1AADRA1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 US disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 EP disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD REN 1/4885ADRA1A 344/4885KCNH2 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.